NOVARTIS AG (NVS) Form 6-K — Oct 27, 2026
Novartis delivered Q3 2026 net sales of USD 14.5 billion, up 4% at constant currencies, with core operating income of USD 6.0 billion, up 10% cc, and core EPS of USD 2.46, up 8% cc. The company raised full-year 2026 guidance, now expecting core operating income to be in line to grow low single-digit, from a previously expected low single-digit decline.
Key figures
- Eps
- 0.63
- Net Income
- 1196000000
- Total Debt
- 46300000000
- Revenue Yoy
- +4% cc / +4% USD (Q3)
- Gross Proceeds
- 0
- Shares Offered
- 0
- Net debt
- 37400000000
- Core eps 9m
- 6.85
- Core eps q3
- 2.46
- Buyback 9m usd
- 4700000000
- Guidance change
- FY26 core operating income raised to 'in line to grow low single-digit' from 'decline low single-digit'
- Free cash flow 9m
- 14002000000
- Net debt dec 2025
- 21900000000
- Core eps growth cc
- +8%
- Entresto q3 change
- -38%
- Free cash flow yoy
- -18%
- Annual dividend paid
- 9100000000
- Del desiran ph3 harbor
- missed primary endpoint (DM1)
- Impairment del desiran
- 1940000000
- Pelacarsen ph3 horizon
- missed primary endpoint (Lp(a))
- Core operating margin q3
- 41.6% (+2.0pp cc)
- Remibrutinib ph3 remodel
- positive in RMS
- Buyback remaining program
- USD 4.9 billion of up-to USD 10 billion
- Core operating income growth cc
- +10%
- Del desiran iprd carrying value
- 5540000000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.